Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study

被引:1
作者
Rouf, Siham [1 ]
Rbiai, Najwa [1 ]
Baibai, Kaoutar [2 ]
Berrich, Jamal [2 ]
Bouchentouf, Toumi [2 ]
Rahmoun, Mohammed [2 ]
Abda, Naima [3 ]
Latrech, Hanane [1 ]
机构
[1] Mohamed First Univ, Mohammed VI Univ Hosp, Med Sch, Diabetol & Endocrinol, Oujda, Morocco
[2] Mohamed First Univ, Natl Sch Appl Sci, Res Lab Appl Sci, Oujda, Morocco
[3] Mohammed First Univ, Lab Epidemiol Clin Res & Publ Hlth, Oujda, Morocco
关键词
telemedicine; type; 1; diabetes; if-diabete; metabolic control; hypoglycemia; INTENSIFIED INSULIN THERAPY; RANDOMIZED CONTROLLED-TRIAL; GLYCEMIC CONTROL; SELF-CARE; HYPOGLYCEMIA; SYSTEM; MANAGEMENT; EDUCATION; TELECARE; PROGRAM;
D O I
10.7759/cureus.12646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 +/- 3 years. Over a six months' period of the study, the mean HbA1c level decreased from 8.3 +/- 0.8% to 7.0 +/- 0.5 % with a reduction in mild hypoglycemic events' frequency from 5 +/- 3 to 1 +/- 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 +/- 0.5 to 5 +/- 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Clinical Safety and Feasibility of the Advanced Bolus Calculator for Type 1 Diabetes Based on Case-Based Reasoning: A 6-Week Nonrandomized Single-Arm Pilot Study
    Reddy, Monika
    Pesl, Peter
    Xenou, Maria
    Toumazou, Christofer
    Johnston, Desmond
    Georgiou, Pantelis
    Herrero, Pau
    Oliver, Nick
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (08) : 487 - 493
  • [2] An mHealth-Based Intervention for Adolescents With Type 1 Diabetes and Their Parents: Pilot Feasibility and Efficacy Single-Arm Study
    Holtz, Bree
    Mitchell, Katharine M.
    Holmstrom, Amanda J.
    Cotten, Shelia R.
    Dunneback, Julie K.
    Jimenez-Vega, Jose
    Ellis, Deborah A.
    Wood, Michael A.
    JMIR MHEALTH AND UHEALTH, 2021, 9 (09):
  • [3] No Effect of an Automated Bolus Calculator in Pediatric Patients with Type 1 Diabetes on Multiple Daily Injections: The Expert Kids Study
    Madsen, Jens Otto Broby
    Casteels, Kristina
    Fieuws, Steffen
    Kristensen, Kurt
    Vanbrabant, Koen
    Ramon-Krauel, Marta
    Johannesen, Jesper
    Bontinck, Magda
    Devisscher, Carine
    Goicoechea, Irune
    Hertz, Anne Marie
    Jorgensen, Lene Kolle
    Vandoorne, Eva
    Yoldi, Carmen
    Casteels, Kristian
    Corripio, Raquel
    Gonzalez-Vergaz, Amparo
    Hernandez, Roque Cardona
    Sanchez, Jacobo Perez
    Van Aken, Sara
    Vanbesien, Jesse
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (06) : 322 - 328
  • [4] A pilot study of Pharmacist-Dietician Collaborative support and Advice (PDCA) for patients with type 2 diabetes in community pharmacy: A single-arm, pre-post study
    Shoji, Masaki
    Sakane, Naoki
    Ito, Naoki
    Sunayama, Keiji
    Onda, Mitsuko
    PHARMACY PRACTICE-GRANADA, 2022, 20 (02):
  • [5] Bolus Calculator Reduces Hypoglycemia in the Short Term and Fear of Hypoglycemia in the Long Term in Subjects with Type 1 Diabetes (CBMDI Study)
    Vallejo Mora, Maria del Rosario
    Carreira, Monica
    Teresa Anarte, Maria
    Linares, Francisca
    Olveira, Gabriel
    Gonzalez Romero, Stella
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (07) : 402 - 409
  • [6] A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study
    Vlasakova, Martina
    Muzik, Jan
    Holubova, Anna
    Fiala, Dominik
    Arsand, Eirik
    Urbanova, Jana
    Zdarskaka, Denisa Janickova
    Brabec, Marek
    Broz, Jan
    JMIR FORMATIVE RESEARCH, 2023, 7
  • [7] Real-World Effectiveness and Safety of Hydrogen Inhalation in Chinese Patients with Type 2 Diabetes: A Single-Arm, Retrospective Study
    Ji, Hongxiang
    Zhao, Ziyi
    Liu, Zeyu
    Sun, Ruitao
    Li, Yuquan
    Ding, Xiaoheng
    Ni, Tongshang
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 2039 - 2050
  • [8] Safety and Efficacy of an Adaptive Bolus Calculator for Type 1 Diabetes: A Randomized Controlled Crossover Study
    Unsworth, Rebecca
    Armiger, Ryan
    Jugnee, Narvada
    Thomas, Maria
    Herrero, Pau
    Georgiou, Pantelis
    Oliver, Nick
    Reddy, Monika
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (06) : 414 - 425
  • [9] Feasibility and acceptability of a telehealth intervention for improving peer relationships for adolescents with neurofibromatosis type 1: a single-arm pilot study
    Glad, Danielle M.
    Pardej, Sara K.
    Olszewski, Ellen
    Klein-Tasman, Bonita P.
    JOURNAL OF PEDIATRIC PSYCHOLOGY, 2024, 49 (09) : 647 - 655
  • [10] Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study
    Velojic-Golubovic, Milena
    Ciric, Vojislav
    Dimitrijevic, Marija
    Kovic, Tijana
    Mitic, Milica
    Olujic, Biljana
    Pevac, Natasa
    Radenkovic, Sasa
    Radojkovic, Danijela
    Vukadinovic, Selena
    Popovic, Djordje S.
    DIABETES THERAPY, 2021, 12 (07) : 2049 - 2058